Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of ICP-B381 in Patients With Advanced Solid Tumors

13 november 2026 uppdaterad av: Beijing InnoCare Pharma Tech Co., Ltd.

An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors

To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

348

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200032
        • Rekrytering
        • Fudan University Shanghai Cancer Center
        • Kontakt:
          • DingWei Ye, M.D.
          • Telefonnummer: 021-64175590*81807
          • E-post: dwyeli@163.com

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Participants must be at least 18 years old.
  2. Participants thoroughly understand study procedures, and voluntarily sign the written ICF
  3. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
  4. Expected survival time ≥3 months.
  5. Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
  6. Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
  7. The organ function level must meet the prescribed standards
  8. All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
  9. Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
  10. Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
  11. Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
  12. Participants can communicate well with the Investigator and can complete the study according to the study protocol

Exclusion Criteria:

  1. Other active malignant tumors occurred within 3 years before the first administration of the study drug
  2. Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
  3. Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
  4. Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
  5. Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
  6. Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
  7. Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
  8. Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
  9. Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
  10. Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
  11. Situations that the investigator deems unsuitable for participating in this study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: ICP-B381

ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
Tidsram: 2 years
2 years
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
Tidsram: 2 years
2 years
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
Tidsram: 2 years
2 years
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
Tidsram: 2 years
2 years
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
Tidsram: 2 years
2 years
The optimal dosing regimen for the subsequent study of ICP-B381
Tidsram: 2 years
2 years

Sekundära resultatmått

Resultatmått
Tidsram
Total överlevnad (OS)
Tidsram: 2 år
2 år
Duration of Response (DOR)
Tidsram: 2 år
2 år
Objektiv svarsfrekvens (ORR)
Tidsram: 2 år
2 år
Maximal koncentration (Cmax)
Tidsram: 2 år
2 år
Disease Control Rate (DCR)
Tidsram: 2 år
2 år
Time to Maximum Plasma Concentration (Tmax)
Tidsram: 2 years
2 years
Half-life (T1/2)
Tidsram: 2 years
2 years
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
Tidsram: 2 years
2 years
Apparent Clearance Rate (CL/F)
Tidsram: 2 years
2 years
Terminal Apparent Volume of Distribution (Vz/F)
Tidsram: 2 years
2 years
Steady-state Pharmacokinetic Parameters
Tidsram: 2 years
2 years
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
Tidsram: 2 years
2 years
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
Tidsram: 2 years
2 years
Participants with prostate cancer: PSA90 response rate
Tidsram: 2 years
2 years
Participants with prostate cancer:12-week PSA response rate
Tidsram: 2 years
2 years
Participants with prostate cancer: time to PSA progression (TTPP)
Tidsram: 2 years
2 years
Time to First Subsequent Therapy (TFST)
Tidsram: 2 years
2 years
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
Tidsram: 2 years
2 years
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
Tidsram: 2 years
2 years
Incidence rate of anti-drug antibody (ADA) against ICP-B381
Tidsram: 2 years
2 years
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
Tidsram: 2 years
2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 oktober 2026

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 juli 2028

Studieregistreringsdatum

Först inskickad

22 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

22 oktober 2026

Första postat (Faktisk)

28 oktober 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • ICP-CL-01901

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera